Mobidiag to Attend the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam, the Netherlands
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, will be attending the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, the Netherlands, from 13-16 April 2019. Organised by Europe’s leading society in clinical microbiology and infectious diseases, the ECCMID annual meeting brings together leading experts from around the world, including innovative commercial companies specializing in diagnostics.
Mobidiag will be hosting an Exhibit Booth (#1.62, Hall 3) at ECCMID. The Company will demonstrate its proprietary diagnostic solutions, Amplidiag® and Novodiag® and showcase how these can be used to provide fast, accurate and accessible solutions for the diagnosis of infectious diseases and, particularly in antimicrobial resistance.
Mobidiag has made significant progress in recent months, including:
- Mobidiag Joint Venture with Autobio Diagnostics and €10m equity investment (17/12/18)
- Mobidiag Announces Release of Novodiag® CarbaR+ test allowing rapid, cost-effective molecular testing for ‘superbacteria’ and associated drug resistance (19/01/19)
- Mobidiag signed multiple international agreements for distribution of its Amplidiag® and Novodiag® diagnostic solutions (25/02/19)
Mobidiag’s management, R&D and commercial & marketing teams will be available to address any questions. If you would like to arrange a meeting with the team, please contact the Company by email: firstname.lastname@example.org .
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose affordable, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
Consilium Strategic Communications
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-DTCP25.6.2019 11:12:09 CEST | Pressemeddelelse
DTCP Closes USD 350 Million Venture and Growth Fund Including Capital From Institutional and Corporate Investors
DIGITAL-ELEMENT25.6.2019 10:04:04 CEST | Pressemeddelelse
ClickFellas Chooses Digital Element to Increase Accuracy of IP Geotargeting Services
TEMENOS25.6.2019 10:02:13 CEST | Pressemeddelelse
Banque du Caire, One of the Largest State-owned Banks in Egypt, Goes Live With Temenos to Redefine Digital Customer Experience
KOHLI-VENTURES25.6.2019 10:02:13 CEST | Pressemeddelelse
Tech Veteran Tej Kohli Calls for a Democratisation of AI
MDS-GLOBAL-LTD25.6.2019 10:02:03 CEST | Pressemeddelelse
iD Mobile Signs New MDS Global Contract to Take Advantage of Cloud-Based BSS Solution
ENECO-HOLDINGS25.6.2019 09:32:11 CEST | Pressemeddelelse
Eneco Holdings, Inc. to Spark Fuel Revolution with Low-Price, High-Concentration, Scalable Hydrogen-generation Technology
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum